[{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Cerecor"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Aevi Genomic Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : CERC-002 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 02, 2020

                          Lead Product(s) : CERC-002

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          February 03, 2020

                          Lead Product(s) : Rislenemdaz

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Cerecor

                          Deal Size : $22.1 million

                          Deal Type : Acquisition

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 01, 2018

                          Lead Product(s) : Fasoracetam

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 29, 2017

                          Lead Product(s) : Fasoracetam

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 30, 2016

                          Lead Product(s) : NFC-1

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of DiGeorge Syndrome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 12, 2016

                          Lead Product(s) : NFC-1

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : NFC-1 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 19, 2016

                          Lead Product(s) : NFC-1

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 10, 2015

                          Lead Product(s) : MDGN201

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Medgenics Medical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 04, 2015

                          Lead Product(s) : MDGN201

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Medgenics Medical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Lead Product(s) : NFC-1

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase I

                          Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 10, 2014

                          Lead Product(s) : NFC-1

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank